Reports Q2 revenue $256,000, consensus $190,000. “We saw a significant increase in sales during the second quarter of 2023, with revenue up 115% over the second quarter of 2022, and up 131% compared to the first quarter of 2023. This growth was due in part to patients purchasing PoNS prior to the expiration of PTAP at the end of June. We were pleased by the success of PTAP in creating access to PoNS in the early stages of our U.S. launch,” said Dane Andreeff, president and CEO of Helius.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HSDT:
- Is HSDT a Buy, Before Earnings?
- Helius Medical adds Montefiore Medical to PoNSTEP
- Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program
- Helius Medical Technologies, Inc. to Release Second Quarter 2023 Financial Results on August 10, 2023
- Helius Medical expands stroke trial at MUSC
